Welcome to our dedicated page for Westlake Chem Partners Lp SEC filings (Ticker: WLKP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Westlake Chemical Partners LP (NYSE: WLKP) SEC filings page on Stock Titan provides access to the partnership’s key regulatory documents, along with AI-powered summaries to help interpret complex disclosures. Westlake Chemical Partners is a limited partnership formed by Westlake Corporation to operate, acquire and develop ethylene production facilities and other qualified assets, and its filings offer detailed insight into this structure.
Through its Annual Reports on Form 10-K, the partnership presents audited financial statements, discussions of its ethylene production assets, and explanations of its commercial arrangements with Westlake, including the Ethylene Sales Agreement and Feedstock Supply Agreement. Quarterly Reports on Form 10-Q update investors on interim financial performance, MLP distributable cash flow, coverage ratios and EBITDA, as well as the effects of plant turnarounds and maintenance capital expenditures.
Current reports on Form 8-K document material events such as the renewal of the Ethylene Sales Agreement and Feedstock Supply Agreement through specified dates, amendments to the Services and Secondment Agreement and Omnibus Agreement, and the announcement of quarterly earnings results. These filings describe how 95% of OpCo’s ethylene production is sold to Westlake under a fixed cash margin formula and outline Westlake’s ownership interests and indemnification obligations.
Stock Titan’s interface highlights real-time updates from EDGAR and uses AI to summarize lengthy 10-K and 10-Q filings, making it easier to understand revenue drivers, non-GAAP metrics like MLP distributable cash flow and EBITDA, and the partnership’s capital structure, including long-term debt payable to Westlake. Users can also review filings that relate to distributions, tax notices for non-U.S. investors and other governance matters.
For investors analyzing WLKP’s regulatory history, this page offers a focused view of how Westlake Chemical Partners reports its ethylene operations, partnership arrangements and financial performance over time.
Jean-Marc Gilson, President, CEO and Director of Westlake Chemical Partners LP (WLKP), amended a prior Form 4 to disclose an additional insider purchase. The amendment reports that 320 common units were purchased on 08/28/2024 at a price of $22.95 per unit, bringing the reporting persons beneficial ownership to 3,427 common units. The amendment states the 320 units were inadvertently omitted from the original Form 4 filed for the same date.
The Form 4/A is signed by a power of attorney on 08/28/2025 and clarifies that this filing supplements, rather than replaces, the original disclosure.
Westlake Chemical Partners LP (WLKP) filing a Form 144 notifies the proposed sale of 12,000 common shares through UBS Financial Services (Weehawken, NJ) with an approximate aggregate market value of $263,400. The shares represent part of the issuer's outstanding common of 35,238,556 and the sale is scheduled for 08/15/2025 on the NYSE. The shares were originally acquired in an IPO purchase on 07/30/2014 and paid in cash. The filer declares no sales in the past three months and signs the required representation regarding material nonpublic information.
Energy Income Partners, LLC and four named partners reported beneficial ownership of limited partner units in Westlake Chemical Partners LP’s common unit class. The group holds an aggregate 1,774,544 units, representing 5.04% of the class, with 403,727 units held with sole voting and dispositive power and 1,370,817 units held with shared voting and dispositive power. The filing is a Schedule 13G and includes a certification that the securities are held in the ordinary course of business and were not acquired to change or influence control of the issuer.
Westlake Chemical Partners LP (WLKP) – Form 4 insider transaction
Director Randy Woelfel reported a matched exercise-and-sale on 8 Aug 2025 covering 4,882 common units:
- Exercise (Code M): 4,882 phantom units converted into an equal number of common units on 7 Aug 2025.
- Sale (Code D): the same 4,882 common units immediately sold at $21.96, generating proceeds of roughly $107 k.
After the transactions, Woelfel’s direct ownership fell from 28,795 to 23,913 common units (≈17% reduction) and no derivative (phantom) units remain outstanding. He also received a separate grant of 5,005 new phantom units on 6 Aug 2025 that will settle in common units one year later.
No 10b5-1 trading plan was indicated, and the filing involves only one reporting person. While the dollar value is modest relative to WLKP’s market capitalization, insider sales can be viewed cautiously by investors, particularly when they reduce ownership levels.
Westlake Chemical Partners LP (WLKP) filed a Form 4 reporting insider activity by director Lisa A. Friel. On 08-06-2025 she received 5,005 phantom units, each economically equivalent to a common unit. On 08-07-2025 she exercised 4,882 of those phantom units into common units (Code M) and sold 2,441 units at $21.96 (Code D). After the transactions she directly owns 7,163 common units.
- Approximate gross value: ~US$107 k (exercise) with ~US$53 k in sale proceeds.
- No phantom units remain; all derivative positions were converted or settled.
- Friel remains a director of the GP, maintaining equity alignment with unitholders.
Director G. Steven Finley filed a Form 4 for Westlake Chemical Partners LP (WLKP) covering two transactions on 8-6-25 and 8-7-25.
- 8 Aug 2025 grant: Finley received 5,005 phantom units (economic equivalent of common units). These vest/exercisable 8-6-26 and expire 9-6-26; cost basis reported as $0.
- 7 Aug 2025 conversion: Finley exercised 4,882 phantom units (Code M), acquiring the same number of WLKP common units at no cash cost. Direct common-unit holdings rose to 31,930 units from approximately 27,048, an ~18% increase.
No open-market purchases or sales were reported, and derivative holdings after the reported transactions stand at the newly granted 5,005 phantom units. The filing signals continued equity alignment by a board member but does not involve cash transactions or changes to public float.